Veristat, a scientific full-service clinical research organization (CRO) and consultancy, has acquired Instat Clinical Research, an biometrics CRO with a 20-year track record of transforming complex data into precise study results.
The acquisition strengthens Veristat’s expertise and solutions in biometrics, one of the most impactful activities in the clinical research workflow. Instat brings complementary proficiencies to Veristat’s global data management, biostatistics, and statistical programming teams, with staff located in the United States and India. Instat has extensive experience partnering with clients to optimize how clinical studies are designed and how data is collected, integrated, and analyzed to meet the requirements of global regulatory organizations across the United States, Europe, and Asia. The addition of the India location complements Veristat’s existing facility in Taipei, offering clients access to a round-the-clock team to contribute timely data and accelerate drug development cycle times.
“Our clients must be able to understand and quickly act on the insights gleaned from their study data in both the trial design and trial execution stages of their programs,” said Patrick Flanagan, Chief Executive Officer of Veristat. “Instat brings a proven track record having supported over 100 sponsor-led clinical studies, authoring over 150 statistical analysis plans, and participating in over 30 regulatory submissions. The addition of Instat’s seasoned talent will further strengthen our ability to help clients bring their drugs and biologics to market faster.”
Both Veristat’s and Instat’s biometrics teams have significant expertise in statistical consulting, clinical data programming, statistical analysis, data management, and project management, supporting the development of complex biologic and drug therapies to treat rare cancers, central nervous system/neurological disorders, endocrine/metabolic disorders, and infectious diseases as well as various other therapeutic areas.
“As biotherapeutics continue to evolve, so does biometrics, the unequivocal underpinning of clinical research,” stated Kyle McBride, CEO and Co-founder of Instat. “Instat possesses the ideal mix of talent, technical acumen, and technology solutions to keep pace with this change and bring statistical understanding across the clinical development lifecycle. On behalf of the entire Instat team, we are thrilled to begin our next chapter with Veristat. Our joining allows us to offer world-class end-to-end services to our clients while acting with the speed and effectiveness our customers have come to rely on.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!